Nov 16, 2019 2:00am EST Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
Nov 01, 2019 8:00am EDT Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019
Oct 09, 2019 8:00am EDT Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
Oct 01, 2019 8:00am EDT Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
Sep 30, 2019 8:45am EDT Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
Sep 09, 2019 8:00am EDT United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
Aug 27, 2019 8:00am EDT Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
Aug 01, 2019 7:15am EDT Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
